Current status of genetics for prediction, prognosis, and gene therapy

Current Opinion in Otolaryngology and Head and Neck Surgery

Volumn 8, Issue 2, 2000, Pages 69-79

  Partridge, Maxine ^a  

^a KING S COLLEGE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; ANTISENSE OLIGODEOXYNUCLEOTIDE; BIOLOGICAL MARKER; BISPECIFIC ANTIBODY; CYTOKINE; DNA; GANCICLOVIR; KERATIN; LIPOSOME; MYC PROTEIN; ONYX 015; PRODRUG; PROTEIN BAX; PROTEIN P16; PROTEIN P21; PROTEIN P53; RECOMBINANT PROTEIN; RETINOBLASTOMA PROTEIN; THYMIDINE KINASE; TUMOR ANTIGEN;

ADENOVIRUS; ANTINEOPLASTIC ACTIVITY; CANCER ADJUVANT THERAPY; CANCER DIAGNOSIS; CANCER RECURRENCE; CANCER RISK; CARCINOGENESIS; CELL SEPARATION; CHEMOSENSITIVITY; CLINICAL TRIAL; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; EXPRESSION VECTOR; FLU LIKE SYNDROME; GENE MUTATION; GENE TARGETING; GENE THERAPY; GENETIC DISORDER; GENETICS; HEAD AND NECK CANCER; HUMAN; IMMUNOCYTOCHEMISTRY; MICROSATELLITE INSTABILITY; MINIMAL RESIDUAL DISEASE; NONHUMAN; OCCULT CANCER; PRECANCER; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; RADIOSENSITIVITY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; SUICIDE GENE; TUMOR SUPPRESSOR GENE; VIRUS RECOMBINANT;

EID: 0034463977     PISSN: 10689508     EISSN: None     Source Type: Journal    
DOI: 10.1097/00020840-200004000-00001     Document Type: Review

References (70)

1. The biology of cancer
2. Genetic progression model for head and neck cancer: Implications for field cancerization
3. The location of candidate tumour suppressor gene loci at chromosomes 3p, 8p and 9p for oral squamous cell carcinoma
4. Localization of a novel tumor suppressor gene loci on chromosome 9p21-22 in oral cancer
5. Frequent allelic loss and homozygous deletion in chromosome band 8p23 in oral cancer
6. The DUTT1 gene, a novel NCAM family member is expressed in developing murine neural tissues and has an unusually broad pattern of expression
7. Molecular cloning of a candidate tumor suppressor gene, DLC1, from chromosome 3p21.3
8. Novel tumour suppressor locus in human chromosome region 3p14.2
9. Multiple head and neck tumors: Evidence for a common clonal origin
10. Allelotype of squamous cell carcinoma of the head and neck: Fractional allele loss correlates with survival
11. LOH at 3p correlates with a poor survival in oral squamous cell carcinoma
12. 9p21 deletion correlates with recurrence in head and neck cancer
13. Loss of heterozygosity at 11q23 in squamous cell carcinoma of the head and neck is associated with recurrent disease
14. Loss of heterozygosity on chromosome 2q: Possibly a poor prognostic factor in head and neck cancer
15. The prognostic significance of allelic imbalance at key chromosomal loci in oral cancer
16. Patient-specific mutation databases for oral cancer
17. Phenotypic and genotypic disparity in premalignant lesions: Of calm water and crocodiles
18. Frequent microsatellite alterations at chromosomes 9p21 and 3p14 in oral premalignant lesions and their value in cancer risk assessment
19. Field cancerisation of the oral cavity: Comparison of the spectrum of molecular alterations in cases presenting with both dysplastic and malignant lesions
20. Allelic imbalance at chromosomal loci implicated in the pathogenesis of oral precancer; cumulative loss and its relationship with progression to cancer
21. Distinguishing second primary tumors from lung metastases in patients with head and neck squamous cell carcinoma
22. Phenotype and genotype of advanced premalignant head and neck lesions after chemopreventive therapy
23. Apoptosis, p53 and tumor cell sensitivity to anticancer agents
24. Changes of mutant-type p53 expression in squamous cell carcinoma of the head and neck during radiation therapy and its clinical significance: Comparison of an immunohistochemical method and PCR-SSCP assay
25. Improved survival in the treatment of squamous carcinoma of the oral tongue
26. Head and neck cancer and precancer: Can we use molecular genetics to make better predictions?
27. Molecular assessment of histopathological staging in squamous-cell carcinoma of the head and neck
28. Immunocytologic detection of isolated tumour cells in bone marrow of patients with squamous cell carcinomas of the head and neck region
29. Immunomagnetic separation for enrichment and sensitive detection of disseminated tumour cells for patients with head and neck SCC
30. Identification of a novel cytokeratin 19 pseudogene that may interfere with reverse transcriptase-polymerase chain reaction assays used to detect micrometastatic tumor cells
31. Haematogenous cytokeratin 20 mRNA as a predictive marker for recurrence in oral cancer patients
32. Development of protocols for detection of micrometastases for patients with head and neck cancer: The problem of tumour cells in the monocyte and granulocyte fraction
33. Detection of micrometastasis by cytokeratin 20 RT-PCR is limited due to stable background transcription in granulocytes
34. Sensitive detection of squamous cells in bone marrow and blood of head and neck cancer patients by E-48 reverse transcriptase-polymerase chain reaction
35. Improved methods using the reverse transcriptase polymerase chain reaction to detect tumour cells
36. Efficient gene transfer to human squamous cell carcinomas by the herpes simplex virus type 1 amplicon vector
37. Adenovirus-mediated p53 gene transfer in patients with advanced recurrent head and neck squamous cell carcinoma
38. Efficient gene transfer into human keratinocytes with recombinant adeno-associated virus vectors
39. Intravenous administration of ONYX-015, a selectively replicating adenovirus, induces antitumoral efficacy
40. Restoration of the growth suppression function of mutant p53 by a synthetic peptide derived from the p53 C-terminal domain
41. The Ink4A/ARF locus and its gene products
42. Retargeting to EGFR enhances adenovirus infection efficiency of squamous cell carcinoma
43. Selective gene delivery to head and neck cancer cells via an integrin targeted adenoviral vector
44. Transferrin-liposome-mediated p53 sensitization of squamous cell carcinoma of the head and neck to radiation in vitro
45. In vivo molecular therapy with p53 adenovirus for microscopic residual head and neck squamous carcinoma
46. Apoptosis induction mediated by wild-type p53 adenoviral gene transfer in squamous cell carcinoma of the head and neck
47. Inability to induce the alteration of tumorigenicity and chemosensitivity of p53-null human pancreatic carcinoma cells after the transduction of wild-type p53 gene
48. Failure of wild-type p53 gene therapy in human cancer cells expressing a mutant p53 protein
49. Induction of apoptosis and G2/M arrest by infection with replication-deficient adenovirus at high multiplicity of infection
50. Expression of apoptosis-related genes in human head and neck squamous cell carcinomas undergoing p53-mediated programmed cell death
51. Recombinant adenovirus expressing wild-type p53 is antiangiogenic: A proposed mechanism for bystander effect
52. Adenovirus-mediated wild-type p53 gene transfer as a surgical adjuvant in advanced head and neck cancers
53. Randomized Phase III trial of edatrexate versus methotrexate in patients with metastatic and/or recurrent squamous cell carcinoma of the head and neck
54. A phase II trial with an E1B-deleted adenovirus, ONYX-015, in patients with recurrent refractory head and neck cancer
55. An agent that increases tumor suppressor transgene product coupled with systemic transgene delivery inhibits growth of metastatic lung cancer in vivo
56. Suppression of the immune response to an adenovirus vector and enhancement of intratumoral transgene expression by low-dose etoposide
57. p53 mediated sensitization of squamous cell carcinoma of the head and neck to radiotherapy
58. p53 mutations and locoregional treatment failure in head and neck squamous cell carcinoma
59. In vitro growth suppression by adenoviral transduction of p21 and p16 in squamous cell carcinoma of the head and neck
60. Adenovirally transferred p161NK4/CDKN2 and p53 genes co-operate to induce apoptotic tumor cell death
61. INK4A adenovirus-mediated gene therapy for human head and neck squamous cell cancer
62. Combination E2F-1 and p53 gene transfer does not enhance growth inhibition in human squamous cell carcinoma of the head and neck
63. Adenovirus-mediated gene therapy for human head and neck squamous cell cancer in a nude mouse model
64. Tumor reduction in vivo after adenoviral mediated gene transfer of the herpes simplex virus thymidine kinase gene and ganciclovir treatment in human head and neck squamous cell carcinoma
65. Combination surgery and nonviral interleukin 2 gene therapy for head and neck cancer
66. Combination gene therapy for oral cancer in a murine model
67. The clinical manipulation of angiogenesis: Pathology, side-effects, surprises and opportunities with novel human therapies
68. The molecular basis of the hypoxia response pathway: Tumour hypoxia as a therapy target
69. Adenovirus-mediated p53 gene therapy and Paclitaxel have synergistic efficacy in models of human head and neck, ovarian, prostate and breast cancer
70. Adenovirus-mediated p53 gene therapy has greater efficacy when combined with chemotherapy against human head and neck, ovarian, prostate, and breast cancer